Teva gets EU OK for Symbicort knockoff, is mentioned in Mylan, Actavis Celebrex suits; Will Teva get bigger?;

@FiercePharma: Looking for more megadeal excitement? Don't look at Sanofi, CEO says. Story | Follow @FiercePharma

@TracyStaton: Why pay $100B for AstraZeneca? Let Pfizer's CEO count the reasons. A biggie = "synergies," i.e. cost cuts. More | Follow @TracyStaton

@EricPFierce: The FDA is letting Baxter import saline from a plant in Spain to help ease the shortage in the US. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Allergan to propose to Shire again, but does Irish beauty want to get engaged? Article | Follow @CarlyHFierce

> Teva Pharmaceutical Industries ($TEVA) has gotten the OK from the EU to market its new DuoResp Spiromax multidose dry-powder inhaler, its knockoff of AstraZeneca's ($AZN) blockbuster Symbicort. Release

> Actavis ($ACT) has followed Mylan ($MYL) to court to sue the FDA for granting Teva Pharmaceutical Industries the exclusive generic rights to Pfizer's ($PFE) blockbuster painkiller Celebrex, which goes off patent in May. Story

> Teva may feel pressure to jump into the acquisition boom that has engulfed the pharma industry. Story

> Brazilian drugmaker and consumer goods producer, Hypermarcas, has been gaining market share in the the country by pushing its marketing in the face of a economic slump there. Story

> Massachusetts and other states are setting up a federal fight over FDA's approval of painkiller Zohydro with plans to restrict use even after a court order that they could not impede its use. Story

> Biogen Idec ($BIIB) announced new two-year data for drug candidate Plegridy, its peginterferon beta-1a, long-lasting treatment for relapsing forms of multiple sclerosis (RMS). Release

> Finnish drug maker Orion today reported Q1 an operating profit of €67 million ($93 million), missing analyst estimates but keeping its outlook for the year unchanged. Story

Medical Device News

@FierceMedDev: Luminex reports higher Q1 revenues despite earlier warnings. Article | Follow @FierceMedDev

@VarunSaxena2: Alere to sell stake in BBI Diagnostics Group subsidiary in bid to keep activist investor Coppersmith Capital Management at bay. | Follow @VarunSaxena2

@EmilyWFierce: It's a full menagerie in this week's issue of FierceBiotechResearch: Here's the issue | Follow @EmilyWFierce

@MichaelGFierce: ICYMI from FierceDrugDelivery: Imaging technique maps transdermal drug migration. More | Follow @MichaelGFierce

> Diagnostics firm Indi snags $47.3M for lung tests. More

> GE launches Alzheimer's imaging agent in a cloudy market. Report

> Boston Scientific swings to a profit amid its turnaround plan. Article

Biotech News

@FierceBiotech: Why would Pfizer want to buy AstraZeneca? It's not R&D. More | Follow @FierceBiotech

@JohnCFierce: And that PhII failure wasn't a failure. No sir. Not at all. It was a success. Because Concert says so. All perfectly clear now. | Follow @JohnCFierce

@DamianFierce: BMY's taking the rolling FDA submission approach with much-watched cancer drug nivolumab. Story | Follow @DamianFierce

@EmilyMFierce: Another chink in HIV's armor may point the way to a vaccine. More from FierceBiotech Research | Follow @EmilyMFierce

> Allergan woos J&J, Sanofi while keeping its eyes on Shire, per reports. News

> Amicus shares rally as a revised PhIII delivers positive Fabry data. More

> Bristol-Myers targets neurodegenerative diseases in $725M deal to buy iPierian. Story

Biotech Research News

> Another chink in HIV's armor may point the way to a vaccine. Article

> Protein found in naked mole rats could shed light on Alzheimer's, Parkinson's development. More

> Deadly MERS outbreak blamed on camels. Report

> Rutgers wins $26M NIH grant to help fill lackluster antibiotics pipeline. Report

> Preclinical study advances H. pylori vaccine for stomach cancer. Item

> Single molecule that targets both amyloid and tau could treat Alzheimer's. Story

Pharma Manufacturing News

> Sanofi supply-chain issues again put hurt on its earnings. News

> Baxter adds saline production from Spain to U.S. supply. Story

> FDA loses another top dog in quality to Mylan. Item

> Takeda snags another big subsidy for influenza vaccine plant in Japan. More

> Indian ban on Wockhardt plant lifted by top Indian regulator. Article

And Finally... Cambridge, MA-based MC10 hopes to help athletes of all kinds replicate their best moments with new high-performance electronics that measure biometrics like brain activity, body temperature and heart rate. Story

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.